|
| 孟鲁司特钠联合喜炎平注射液治疗小儿呼吸道合胞病毒感染的应用研究 |
| Application of montelukast sodium combined with Xiyanping injection for respiratory syncytial virus in children |
| |
| DOI：10.3969/j.issn.1007-8134.2021.02.012 |
| 中文关键词: 孟鲁司特钠 喜炎平注射液 呼吸道合胞病毒 粘附分子 炎性因子 安全性 复发率 |
| 英文关键词: montelukast sodium Xiyanping injection respiratory syncytial virus adhesion molecule inflammatory factor safety recurrence rate |
| 基金项目:山东省东营市科技发展计划项目（2017Y017-038） |
|
| 摘要点击次数: 482 |
| 全文下载次数: 438 |
| 中文摘要: |
| 目的 探讨孟鲁司特钠联合喜炎平注射液在治疗小儿呼吸道合胞病毒感染中的临床效果及对粘附分子水平的影响。方法 选取2017年3月—2020年5月在我院诊治的122例小儿呼吸道合胞病毒感染者为研究对象，采用随机数字表法将其分为2组，各61例。对照组采用孟鲁司特钠治疗，观察组在对照组基础上联合喜炎平注射液治疗。治疗2周后评估患者效果，疗程结束后进行6个月随访，比较2组症状消失时间、细胞间粘附分子-1（intercellular adhesion molecule, ICAM-1）和炎性因子水平、安全性及复发率。结果 观察组用药后呼吸困难、咳嗽、哮鸣音及啰音消失时间，住院时间均短于对照组（P均＜0.05）；2组治疗2周后ICAM-1、IL-4、IL-10水平均低于治疗前（P均＜0.05）；IL-12及IFN-γ水平均高于治疗前（P＜0.05）；观察组治疗2周后ICAM-1、IL-4、IL-10水平均低于对照组（P均＜0.05）；IL-12及IFN-γ水平均高于对照组（P均＜0.05）；2组用药过程中恶心呕吐、腹泻便秘、头晕嗜睡发生率及疗程后1、3个月复发率之间差异均无统计学意义（P均＞0.05）；观察组疗程后6个月复发率低于对照组（P＜0.05）。结论 孟鲁司特钠联合喜炎平注射液用于治疗小儿呼吸道合胞病毒感染者，能缩短症状消失时间，有助于降低ICAM-1及炎性因子水平，药物安全性较高，能降低远期复发率，值得推广应用。 |
| 英文摘要: |
| Objective To investigate the clinical effect of montelukast sodium combined with Xiyanping injection in children with respiratory syncytial virus and its influence on the level of adhesion molecules. Methods A total of 122 children with respiratory syncytial virus infection who were admitted to our hospital from March 2017 to May 2020 were included in this study. They were randomly divided into 2 groups, with 61 cases in each group. Patients in the control group were treated with montelukast sodium, and those in the observation group were treated with Xiyanping injection on the basis of the control group. The treatment effect of the patients was evaluated after 2 weeks of treatment, and a 6-month follow-up was conducted after the completion of treatment course. The disappearance time of symptoms, levels of intercellular adhesion molecule 1 (ICAM-1) and inflammatory factors, safety and recurrence rate of 2 groups were compared. Results The time of dyspnea, cough, wheezing and rale disappearance, as well as hospitalization time in the observation group were shorter than those in the control group (P＜0.05). After 2 weeks of treatment, ICAM-1, IL-4 and IL-10 in 2 groups were lower than those before treatment (P＜0.05). The levels of IL-12 and IFN-γ were higher than those before treatment (P＜0.05). After 2 weeks of treatment, ICAM-1, IL-4 and IL-10 in the observation group were lower than those in the control group (P＜0.05). IL-12 and IFN-γ levels were higher than those in the control group (P＜0.05). The incidence of nausea and vomiting, diarrhea, constipation, dizziness and drowsiness in 2 groups and the recurrence rate at 1 and 3 months after treatment showed no statistically significant difference (P＞0.05). The recurrence rate in the observation group was lower than that in the control group at 6 months after treatment (P＜0.05). Conclusions Montelukast sodium combined with Xiyanping injection in children with respiratory syncytial virus infection can shorten the time of symptom disappearance and help to reduce the levels of adhesion molecules and inflammatory factors. It has high drug safety and reduce the long-term recurrence rate, which is worthy of promotion and application. |
|
HTML
查看全文
下载PDF阅读器 |
| 关闭 |